Pfizer’s first new antibody-drug conjugate (ADC) to read out pivotal data after its Seagen acquisition stumbled in a Phase 3 non-small cell lung cancer trial. The failure of sigvotatug vedotin in the NSCLC study injects uncertainty into the company’s ADC strategy and timetable for that asset. The drug is positioned as the inaugural Seagen-derived ADC pivotal readout post-acquisition, increasing scrutiny around whether other Seagen pipeline programs can carry the momentum. Analysts previously highlighted the importance of this ADC’s performance for Pfizer’s forward oncology portfolio. While the study outcome dampens near-term prospects for this specific compound, the broader ADC market continues to depend on differentiating payloads, target biology, and combination sequencing. Pfizer is expected to reassess development next steps following the Phase 3 result. This outcome also highlights the risk profile embedded in ADC transitions from acquisition pipelines into late-stage execution.